FDA finally gets a map of the supplement aisle—and what's actually in it

What it does

This bill requires dietary supplement manufacturers to register their products with the FDA by submitting detailed information including ingredients, labels, warnings, and manufacturing locations. Supplements already on the market have 18 months to register; new products must register before sale. The FDA will create a public database of this information (with some proprietary blend details kept confidential) and assign each product a listing number that must appear on labels.

Why we flagged it

The bill's core mechanism is a mandatory registration and listing system for dietary supplements sold in the US, with public disclosure of most product information. This is a regulatory transparency and traceability measure, not a ban or approval requirement.

What the text implies

• Proprietary blend ingredient amounts remain confidential, limiting consumer transparency on the most opaque aspect of supplement formulations and potentially preserving competitive secrets over full disclosure.
• The 18-month compliance window for existing products may create a temporary enforcement gap during which non-compliant products remain on shelves without penalty until the deadline passes.
• FDA must hire and fund new personnel to manage a potentially large database; if appropriations are insufficient, enforcement and database maintenance could lag, reducing the practical benefit of registration.
• Foreign manufacturers must designate a US agent; this may increase costs for small international suppliers and could consolidate the market toward larger distributors with US infrastructure.

Who it affects

Ordinary consumers gain transparency and traceability of dietary supplements—a largely unregulated category—allowing them to identify products, check ingredients, and report safety issues. The FDA gains enforcement tools to track contaminated or mislabeled products. The compliance burden falls on manufacturers, not consumers, and the public database enables informed choice.

Who stands to gain

• dietary supplement manufacturers (large firms with compliance infrastructure)
• FDA contractors (database development and management)
• US-based supplement distributors and agents

Named in the bill

FDA (Food and Drug Administration), dietary supplement manufacturers, dietary supplement industry, Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 343-3, section 403D, section 552 (Freedom of Information Act)

Where it stands

• Apr 20, 2026 — Introduced · Congress.gov: “Introduced in House”
• Apr 20, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

6 lobbying clients named this bill on 6 disclosure filings across 2 quarters, Mar 2026 to Jun 2026. Those filings disclosed $569,750 in lobbying spend. A filing names 12 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 82% of bills with at least one filing.

Maxine Dexter, the sponsor, reported $365,744 in PAC receipts in the 2026 cycle. $500 of that came from 1 PAC tied to these lobbying clients.

• Consumer Healthcare Products Association — $199,750 on 1 filing
• Unilever United States, Inc. — $130,000 on 1 filing
• Council for Responsible Nutrition — $100,000 on 1 filing
• Pharmavite LLC — $90,000 on 1 filing
• Mondelez International, Inc. — $30,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.